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Not Backﬁre on Sympathetic Overactivity
in Hypertension*
Sverre E. Kjeldsen, MD, PHD,y Fadl Elmula M. Fadl Elmula, MD,y Alexandre Persu, MD, PHDzT he SYMPLICITY HTN-3 (Renal Denervation inPatients With Uncontrolled Hypertension)study was a randomized, sham-controlled
clinical study of the blood pressure (BP)-lowering
effects of renal sympathetic denervation (RDN), which
included ambulatory BPmeasurements (ABPM) as part
of the inclusion criteria and as a secondary endpoint.
The primary results of the study failed to show a larger
reduction in ofﬁce BP and ABPM compared with those
of sham treatment at 6 months (1). In this issue of the
Journal, the SYMPLICITY HTN-3 investigators report
ofﬁce systolic BP (SBP) and ABPM after 1 year in most
of the patients originally randomized to RDN and in
patients in the sham group who did and did not un-
dergo RDN after 6 months (2).SEE PAGE 1314In the original RDN patients (n ¼ 319), ofﬁce SBP
was slightly lower at 12 months than at 6 months
(15.5 vs. 18.9 mm Hg, respectively; p < 0.025), but
ABPMwas not different. Patients who did not undergo
RDN (n ¼ 48) had 32.9 mm Hg reduction in ofﬁce
SBP at 6 months but only 21.4 mm Hg at 12 months.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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went RDN at 6 months (n ¼ 93), they showed 17.7
mm Hg drop in ofﬁce SBP and 9.2 mm Hg in ABPM
at 1 year after randomization. These data support
no further BP reductions after 1 year of follow-up (2).
RDN has been proposed as a new treatment
modality for patients with treatment-resistant hy-
pertension (TRH), a condition deﬁned as persistent
BP elevation despite use of at least 3 antihypertensive
drugs including a diuretic agent. In the earlier
SYMPLICITY HTN-2 trial (3), until recently the only
randomized and controlled study of RDN, it is un-
fortunate that both the patient selection and the
evaluation of efﬁcacy were based on ofﬁce BP rather
than on ABPM, which is a state-of-the art assessment,
particularly in TRH (4). Notwithstanding the contri-
bution of poor drug adherence to TRH (5,6), drug
adherence was not monitored, either at baseline or
during follow-up. This made SYMPLICITY HTN-2
study vulnerable to the Hawthorne effect (i.e.,
patients started taking their drugs as prescribed in
response to the attention devoted to them) (7). The
lack of BP decrease in the control group also raises
concerns that these patients may not have taken
their medications properly in order to keep their BP at
a level that made them eligible for crossover to the
RDN group (8,9). In SYMPLICITY HTN-3, the use of
a sham procedure and wider use of ABPM balanced
the impact of the Hawthorne, white-coat, placebo,
and regression-to-the-mean effects in both arms,
disclosing the size of BP decrease attributable to RDN
to be <2 mm Hg based on ABPM.
It has been suggested that the lack of efﬁcacy of RDN
in SYMPLICITY HTN-3 (1) may be due to lack of sta-
tistical power, to chance (10), or to the fact that the trial
was not rigorously executed (11). Concerns were raised
about whether the RDN was suboptimal because of
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1323insufﬁcient delivery of appropriate energy in the renal
arteries as a consequence of investigator inexperience
(12,13). However, the corresponding analyses are
post-hoc, and the SYMPLICITY HTN-3 ﬁndings are in
line with the results of other recent randomized
clinical trials (14–17). Additionally, despite increased
technical experience of the operators, the BP decrease
6 months after RDN in the crossover group was
not substantially larger than that observed in the
group initially randomized to RDN (2).
Does the failure of SYMPLICITY HTN-3 mean the
end of RDN? Probably not; it has been shown in co-
horts recruited from the third (18) to the ﬁfth decades
of the last century (19,20) that abdominal sympa-
thectomy associated with splanchnicectomy is effec-
tive in the treatment of severe hypertension. The role
of the sympathetic system in the pathophysiology
of hypertension is substantiated by a wealth ofexperimental and clinical arguments (21–25). Accord-
ingly, research should go on to ﬁnd the minority of
patients who are true responders to RDN. A European
network included a large numbers of patients and
suggested that it may be worthwhile searching
for potential predictors of response to RDN (26,27).
However, many patients have probably undergone
unnecessary procedures. By a careful estimate,
20,000 renal arteries have been exposed to RDN in
people with hypertension, and in these patients,
investigators are reporting an increasing number of
cases of renal artery stenosis (28). We must make sure
that RDN is beneﬁcial and does no harm.
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